CD6

Across TCGA pan-cancer cohorts, CD6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD6 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CD6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CD6 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where CD6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.793	0.239	.001	21	view →
LUAD	DFS	Median	All	0.933	0.484	.002	12	view →
HNSC	OS	Quartile	III,IV	0.591	0.891	.029	10	view →
LSCC	OS	Median	II,III,IV	0.597	0.882	.006	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CD6–PDAC (DFS)

Open the PDAC breakdown →